ONS member Rae Norrod, MS, RN, CNS, AOCN®, oncology service line manager at Kettering Health Network in Ohio and member of the West Central Ohio ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss how oncology nurses can safely administer irinotecan chemotherapy and manage its associated side effects and adverse events. This episode is part of an ongoing series about outpatient oncology drug infusion. The others are linked in the episode notes.

Music Credit: "Fireflies and Stardust" by Kevin MacLeod

Licensed under Creative Commons by Attribution 3.0

The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation.

Episode Notes

Check out these resources from today’s episode:

• The NCPD activity for this episode has expired, but you can still earn NCPD through many other Oncology Nursing Podcast episodes. Find a full list of opportunities.
• Previous Oncology Nursing Podcast episodes on outpatient oncology drug infusion
• ONS Voice article: The Case of the Pancreatic Phenomenon
• Oncology Nursing Forum article: Allelic Expression of Phase II Metabolizing Enzymes and Relationship to Irinotecan Toxicity
• ONS book: Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (Fourth Edition)
• ONS Communities thread on administering premeds to prevent diarrhea
• ONS learning library on safe handling of hazardous drugs
• ONS symptom management interventions for chemotherapy-induced diarrhea and mucositis
• ONS position statement: Education of the Registered Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies
• Irinotecan package insert
• Liposomal irinotecan package insert
• National Cancer Institute information on irinotecan

To discuss the information in this episode with other oncology nurses, visit the ONS Communities. 

To provide feedback or otherwise reach ONS about the podcast, email [email protected].